Logo image of RLAY

RELAY THERAPEUTICS INC (RLAY) Stock Fundamental Analysis

NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD

2.95  +0.1 (+3.51%)

Premarket: 2.86 -0.09 (-3.05%)

Fundamental Rating

4

Taking everything into account, RLAY scores 4 out of 10 in our fundamental rating. RLAY was compared to 560 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RLAY as it has an excellent financial health rating, but there are worries on the profitability. RLAY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RLAY has reported negative net income.
In the past year RLAY has reported a negative cash flow from operations.
RLAY had negative earnings in each of the past 5 years.
In the past 5 years RLAY always reported negative operating cash flow.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

RLAY's Return On Assets of -38.76% is in line compared to the rest of the industry. RLAY outperforms 57.68% of its industry peers.
The Return On Equity of RLAY (-43.42%) is better than 68.57% of its industry peers.
Industry RankSector Rank
ROA -38.76%
ROE -43.42%
ROIC N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

7

2. Health

2.1 Basic Checks

RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RLAY has been increased compared to 1 year ago.
Compared to 5 years ago, RLAY has more shares outstanding
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.10, we must say that RLAY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RLAY (0.10) is better than 65.18% of its industry peers.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.1
ROIC/WACCN/A
WACC9.48%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 15.95 indicates that RLAY has no problem at all paying its short term obligations.
The Current ratio of RLAY (15.95) is better than 90.18% of its industry peers.
RLAY has a Quick Ratio of 15.95. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 15.95, RLAY belongs to the top of the industry, outperforming 90.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.95
Quick Ratio 15.95
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

RLAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.53%, which is quite good.
Looking at the last year, RLAY shows a very negative growth in Revenue. The Revenue has decreased by -60.83% in the last year.
Measured over the past years, RLAY shows a very strong growth in Revenue. The Revenue has been growing by 48.92% on average per year.
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)-60.83%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%-23.26%

3.2 Future

The Earnings Per Share is expected to grow by 14.38% on average over the next years. This is quite good.
Based on estimates for the next years, RLAY will show a very strong growth in Revenue. The Revenue will grow by 83.83% on average per year.
EPS Next Y19.19%
EPS Next 2Y9.47%
EPS Next 3Y5.94%
EPS Next 5Y14.38%
Revenue Next Year-40.07%
Revenue Next 2Y27.02%
Revenue Next 3Y45.59%
Revenue Next 5Y83.83%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Also next year RLAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.47%
EPS Next 3Y5.94%

More info and screens

0

5. Dividend

5.1 Amount

RLAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELAY THERAPEUTICS INC

NASDAQ:RLAY (5/28/2025, 8:00:02 PM)

Premarket: 2.86 -0.09 (-3.05%)

2.95

+0.1 (+3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners82.86%
Inst Owner Change4.68%
Ins Owners1.92%
Ins Owner Change1.7%
Market Cap505.75M
Analysts84.21
Price Target17.34 (487.8%)
Short Float %14.1%
Short Ratio6.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.5%
Min EPS beat(2)19.53%
Max EPS beat(2)21.46%
EPS beat(4)4
Avg EPS beat(4)15.61%
Min EPS beat(4)7.69%
Max EPS beat(4)21.46%
EPS beat(8)7
Avg EPS beat(8)12.57%
EPS beat(12)9
Avg EPS beat(12)9.64%
EPS beat(16)10
Avg EPS beat(16)-14.85%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)3053.38%
Min Revenue beat(4)-100%
Max Revenue beat(4)12513.5%
Revenue beat(8)3
Avg Revenue beat(8)2332.03%
Revenue beat(12)4
Avg Revenue beat(12)1545.81%
Revenue beat(16)5
Avg Revenue beat(16)1175.79%
PT rev (1m)-14.57%
PT rev (3m)-20.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.34%
EPS NY rev (1m)8.88%
EPS NY rev (3m)28.19%
Revenue NQ rev (1m)-9.99%
Revenue NQ rev (3m)-80%
Revenue NY rev (1m)100.74%
Revenue NY rev (3m)164.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 50.54
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.46
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0.06
BVpS4.54
TBVpS4.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.76%
ROE -43.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.93%
Cap/Sales 20.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.95
Quick Ratio 15.95
Altman-Z 0.1
F-Score3
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)111.54%
Cap/Depr(5y)95.45%
Cap/Sales(3y)230.95%
Cap/Sales(5y)161.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y19.19%
EPS Next 2Y9.47%
EPS Next 3Y5.94%
EPS Next 5Y14.38%
Revenue 1Y (TTM)-60.83%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%-23.26%
Revenue Next Year-40.07%
Revenue Next 2Y27.02%
Revenue Next 3Y45.59%
Revenue Next 5Y83.83%
EBIT growth 1Y43.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.6%
EBIT Next 3Y3.6%
EBIT Next 5Y8.81%
FCF growth 1Y17.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.05%
OCF growth 3YN/A
OCF growth 5YN/A